Rhodia announces the divestment project to Novacap for its salicylic and acetaminophen activities. Salicylates, which are used as active ingredients in the pharmaceutical industry (aspirin, acetaminophen) or as synthesis intermediates (salicylic acid, methyl salicylate), represent the last pharmaceutical chemistry business remaining within the Group.

The Group?s salicylic and acetaminophen activities whose principal production sites are located in France, Thailand, China and Brazil employ approximately 390 people.

The finalization of this divestment project should take place over the next few months, once consultations with the employee? representatives have been completed and the necessary authorizations required by law have been obtained.